Table 1.
Clinical studies about prognostic role of tumor-associated macrophages (TAM) in Hodgkin lymphoma.
| Reference | Number of Patients | Marker | Antibody | Cut-Off | Survival Correlation |
|---|---|---|---|---|---|
| Steidl et al. [115] | 166 | CD68 | KP1 | Steidl score (<5%, 5–25%, >25%) |
Inferior PFS, DSS |
| Azambuja et al. [116] | 265 | CD68, CD163 |
KP1 10D6 |
Steidl score | No |
| Cencini et al. [117] | 200 | CD68 | KP1 | Steidl score | No |
| Agur et al. [118] | 98 | CD68 | PGM1 | Steidl score | No |
| Cuccaro et al. [119] | 102 | CD68 | PGM1 | Steidl score | Inferior PFS |
| Touati et al. [120] | 158 | CD68 | PGM1 | <25%, ≥25% | Inferior PFS, OS |
| Kayal et al. [121] | 100 | CD68 | (CD68/G2) | Steidl score <25%, >25%; <12.9%, >12.9% (the quartiles) <18.2%, >18.2% (median) |
No No No |
| Klein et al. [122] | 88 | CD68, CD163 |
KP1 10D6 |
<25%, >25%; <25%, >25% |
No Inferior OS |
| Yoon et al. [123] | 144 | CD68, CD163 |
KP1 10D6 |
<20%, >20% <20%, >20% |
Inferior EFS, DSS, OS Inferior EFS, DSS, OS |
| Tan et al. [124] | 287 | CD68, CD163 |
KP1 10D6 |
<12.7%, >12.7% 16.8% (CD163) |
Inferior FFS, OS Inferior FFS, OS |
| Greaves et al. [125] | 90 | CD68 | KP1 | <5%, 5–15%, >15% | Inferior FFTF, OS |
| Jakovic et al. [126] | 52 | CD68 | PGM1 | <25%, ≥25% | Inferior EFS, OS |
| Kamper et al. [127] | 288 | CD68, CD163 |
KP1 10D6 |
<7.8%, ≥7.8% <21.1%, ≥21.1% |
Inferior EFS, OS Inferior EFS, OS |
| Werner et al. [128] | 76 | CD68, CD163 |
PGM1 10D6 |
<724, 725–937, ≥938 <769, 770–1325, ≥1326 |
Inferior DSS Inferior DSS, OS (NS) |
| Karihtala et al. [129] | 130 | CD68, CD163 |
Ab955 Ab188571 |
Continuous variable Continuous variable |
Inferior OS No |
| Mohamed et al. [130] | 81 | CD68 | Ab955 | <20%, 20–50%, >50% | Inferior DFS, OS |
Abbreviations: PFS, progression-free survival; DSS, disease-specific survival; OS, overall survival; EFS, event-free survival; FFS, failure-free survival; FFTF, freedom from treatment failure; NS, not significant.